explore -WSS

explore

author：hotspot 2025-09-07 06:42:35 - browse：744

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Do more moles mean more problems? Not so, says new study

entertainment

focus

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Report: NIH

What Mike Pence has said that could be used in a Donald Trump trial

Influencer to be charged after chaos erupts in New York City's Union Square

Childbirth

knowledge

explore

entertainment

23andMe had bad news about my health. I wish a person had delivered it

Influencer to be charged after chaos erupts in New York City's Union Square

Supreme Court strikes down use of affirmative action

Health insurers say they are turning to AI to cut costs, improve care

Virginia high school admissions case could be legal follow

2 US Navy sailors arrested for allegedly spying for China

Heart attack and stroke risk calculators need revising

Verily hires former Apple Health leader as chief scientific officer

Medical leaders decry Supreme Court decision on affirmative action

Prosthetic arm enables patients to feel the objects they grip

leisure time

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

TytoCare raises $49 million to build out AI

OTC birth control: A brief history of over the counter pill design

Do more moles mean more problems? Not so, says new study

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Stigma and the return of syphilis

entertainment

Wikipedia

focus

hotspot